TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00712400
Drug: Latanoprost 0.005%, Xalatan®
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
Study: NCT03393715
Drug: Perindopril Oral Tablet
Normalized name: perindopril Oral Tablet
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perindopril oral tablet morning versus evening
Study: NCT02978534
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine concentrations will be observed in women who have already (under the guidance of a physician) decided to continue taking Quetiapine for the treatment of Bipolar Disorder (any subtype) or Schizophrenia during pregnancy.
Study: NCT01170039
Drug: Lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone will be given as 24 mcg orally twice a day.
Study: NCT00535873
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
Study: NCT00629967
Drug: pegylated interferon alpha 2a and ribavirin
Normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
Study: NCT00629967
Drug: Pegylated interferon alfa-2a and ribavirin
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
Study: NCT01198522
Drug: L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine
Normalized name: L19-IL2 Monoclonal antibody-cytokine fusion protein
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29.
Study: NCT02168387
Drug: Acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02168387
Drug: dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01558128
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
Study: NCT03400267
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
Study: NCT03359018
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.
Study: NCT03359018
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
Study: NCT04231552
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
Study: NCT01906801
Drug: Diacerein
Normalized name: diacerein
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00969982
Drug: mifepristone+misoprostol
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
Study: NCT00969982
Drug: misoprostol+placebo
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
Study: NCT04022733
Drug: Moderate neuromuscular block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
Study: NCT04166331
Drug: Dobutamine
Normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
Study: NCT03635021
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle
Study: NCT02026843
Drug: Chorioretinal diseases
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration
Study: NCT03635021
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle
Study: NCT04022733
Drug: Deep neuromuscular block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
Study: NCT00935415
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast 5 mg
Study: NCT00862420
Drug: clopidogrel (SR25990)
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral administration (tablets)
Study: NCT00862420
Drug: ticlopidine
Normalized name: Ticlopidine
DrugBank: Ticlopidine (DB00208)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration (tablets)
Study: NCT01478048
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
Study: NCT01478048
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets; Oral; 20 mg; (Cycles 1\& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until subject meets criteria for discontinuation of study drug
Study: NCT04034251
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (intraperitoneal (IP) and intravenous (IV), Day 1 of each 3-week cycle: Paclitaxel IP - Intraperitoneal paclitaxel (60 mg/m\^2) will be diluted in 500 mL of 0.9% normal saline (NS), to be infused as rapidly as tolerated once per 3-week cycle on Day 1. Paclitaxel IV - Intravenous paclitaxel (80 mg/m\^2) will be administered concomitantly over 3 hours, diluted in 100 to 250 ml of 0.9% NS once per 3-week cycle on Day 1.
Study: NCT04143477
Drug: peficitinib
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral
Study: NCT03660059
Drug: Peficitinib
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral
Study: NCT03660059
Drug: Disease-modifying antirheumatic drugs (DMARDs)
Normalized name: Quinolines, antirheumatic drugs
DrugBank: Quinoline (DB18050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod.
Study: NCT00077766
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.
Study: NCT00077766
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).
Study: NCT01267227
Drug: Pterostilbene 50 mg twice daily
Normalized name: clindamycin
DrugBank: Pterostilbene (DB17939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
Study: NCT01478048
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets; Oral; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
Study: NCT01478048
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution; IV; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
Study: NCT01478048
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets; Oral; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until subject meets criteria for discontinuation of study drug
Study: NCT02739633
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
Study: NCT03713905
Drug: GLS-010
Normalized name: Anti-pd-1 monoclonal antibody gls-010
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Human Anti-PD-1 Monoclonal Antibody
Study: NCT01258569
Drug: Entereg
Normalized name: Entereg
DrugBank: Alvimopan (DB06274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alvimopan (Entereg), an oral peripherally- acting mu-opioid receptor antagonist, is the first and only drug approved by the FDA to accelerate the time to upper and lower GI recovery in after partial large or small bowel resection surgery with primary anastomosis.
Study: NCT01258569
Drug: Entereg
Normalized name: Entereg
DrugBank: Alvimopan (DB06274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, 12 mg 30-300 min pre-op then BID up to 7 days (or 15 total doses)
Study: NCT04263584
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copanlisib vials 60 mg
Study: NCT01625260
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
Study: NCT00294762
Drug: Tarceva
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT00294762
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT00294762
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV
Study: NCT00536913
Drug: Budesonide/formoterol pMDI 40/2.25ug + spacer
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00536913
Drug: Budesonide/formoterol pMDI 40/2.25 ug
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03745599
Drug: Benzydamine
Normalized name: benzydamine
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
Study: NCT02013258
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.
Study: NCT02141477
Drug: Omacetaxine
Normalized name: omacetaxine
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
Study: NCT02141477
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I.
Study: NCT01105286
Drug: Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application
Study: NCT01267227
Drug: Grape Extract
Normalized name: grape extract
DrugBank: Grape (DB10533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape extract 100 mg twice daily for 6-8 weeks
Study: NCT01267227
Drug: Pterostilbene 125 mg twice daily
Normalized name: clindamycin
DrugBank: Pterostilbene (DB17939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pterostilbene 125 mg twice daily for 6-8 weeks
Study: NCT02366364
Drug: NRX-1074 375 mg
Normalized name: NRX-1074
DrugBank: NRX-1074 (DB11784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of 375 mg consumption on Day 1
Study: NCT02366364
Drug: NRX-1074 500 mg
Normalized name: NRX-1074
DrugBank: NRX-1074 (DB11784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of 500 mg consumption on Day 1
Study: NCT02366364
Drug: NRX-1074 750 mg
Normalized name: NRX-1074
DrugBank: NRX-1074 (DB11784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of 750 mg consumption on Day 1
Study: NCT02745145
Drug: Abituzumab 1500 mg
Normalized name: sacituzumab
DrugBank: Abituzumab (DB12775)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Abituzumab 1500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
Study: NCT02745145
Drug: Abituzumab 500 mg
Normalized name: sacituzumab
DrugBank: Abituzumab (DB12775)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Abituzumab 500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
Study: NCT03786796
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib is a crystalline solid, is non-chiral and shows pH-independent solubility of approximately 0.1 mg/mL across the physiological range. Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 mg or 150 mg of drug substance. The 100 mg strength is also available as a yellow, film-coated tablet. The 25 mg, 100 mg and 150 mg strengths of olaparib tablets are composed of the same constituents. The tablet cores comprise: olaparib, copovidone, colloidal silicon dioxide, mannitol and sodium stearyl fumarate. The composition of the green tablet film coating is: hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black. The yellow tablet film coating only differs from the green film coating with the omission of iron oxide black.
Study: NCT04510870
Drug: Ferric Carboxymaltose Injection
Normalized name: ferric carboxymaltose Injection
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.
Study: NCT04510870
Drug: NaCl infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.
Study: NCT02905695
Drug: Chirocaine
Normalized name: Chirocaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01356290
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg/kg, intravenous (iv), biweekly, 1 year
Study: NCT01356290
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3mg/kg, oral, daily, 1 year
Study: NCT01356290
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90mg/m2, oral, daily, 1 year
Study: NCT01356290
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
Study: NCT01356290
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
Study: NCT01356290
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year
Study: NCT03026842
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2/day for 5 days
Study: NCT03026842
Drug: Daunorubicin, Cytarabine
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
Study: NCT03026842
Drug: Mitoxantrone, Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
Study: NCT03026842
Drug: Aclacinomycin, Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
Study: NCT01572610
Drug: RTA 402
Normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day, oral administration
Study: NCT01138852
Drug: Ampicillin-sulbactam
Normalized name: ampicillin-sulbactam
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
Study: NCT01138852
Drug: Cefuroxime
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
Study: NCT02208063
Drug: Telavancin
Normalized name: Telavancin
DrugBank: Telavancin (DB06402)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02208063
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02208063
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02208063
Drug: Synthetic penicillin
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02208063
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00275132
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tarceva (OSI-774, erlotinib) PO 150 mg daily
Study: NCT02844062
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg/m\^2 d1-3
Study: NCT00186953
Drug: Optison
Normalized name: Optison
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m\^2 and escalated at 0.15 ml/m\^2 increments, to 0.275 ml/m\^2 and 0.425ml/m\^2 and 0.500ml/m\^2. We will now continue to escalate the dose of Optison at 0.300ml/m\^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer.
Study: NCT01105065
Drug: brimonidine 0.15%
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop in each eye three times a day for 8 weeks.